Replimune Inc. (REPL): Long-Term Debt to Capital Ratio

Replimune Group, Inc. - graphic logo of issuer REPL

Replimune Group, Inc. (REPL) is currently undergoing clinical trials, aiming to outperform global leaders in treatment efficacy. Meanwhile, cross-border research between the US and Britain is subject to risks stemming from sanctions and patent disputes. This trading chart featuring the 1.02 metric complements the analysis of a business focused on developing modified viruses to destroy solid tumors and activate the body's immune defenses.

REPL - Replimune Group, Inc. Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Replimune Group, Inc. (REPL) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price Replimune Group Inc|REPL - Price Target Chart
- market capitalization data:
Market Capitalization Replimune Group, Inc.|REPL - Enterprise Value
- book capitalization data:
Accounting Value per Share Replimune|REPL - Company Book Value|Market-to-Book Ratio replimune.com|REPL - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Replimune Group, Inc.|REPL - Long-Term Debt to Equity|Current Liabilities to Capital replimune.com|REPL - Company Aggregate Debts|Debt to Net Assets Replimune Group, Inc.|REPL - Company Long-Term Liabilities|Short-Term Debt Replimune
Fundamental company valuation:REPL Replimune Group Inc
Brand item of Replimune Corp

This ratio measures the proportion of long-term liabilities within the equity structure, determining the level of financial stability and the company's reliance on external debt financing. By analyzing the long-term debt-to-equity ratio, an investor can assess the ability of Replimune Group, Inc. (REPL) to fund expensive late-stage clinical trials of oncolytic viruses without a critical risk of insolvency.

Who Replimune Group, Inc. competes with

Long-Term Liabilities to Capital IBRX|Long-Term Debt to Equity Immunocore PLC IMCR|Long-Term Debt to Capital Ratio Janux Corp (JANX)|Arcus Biosciences, Inc. - Long-Term Debt to Capital|zymeworks.com - Long-Term Debt to Equity Ratio|TNGX (Tango Therapeutics, Inc.) - Long-Term Debt to Equity|IOVA: Long-Term Liabilities to Capital|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity CMPX (Compass Therapeutics)|Long-Term Liabilities to Capital lyell.com|IPHA: Long-Term Debt to Capital|Long-Term Indebtedness to Equity pyxisoncology.com PYXS|CGEN: Long-Term Debt to Equity Ratio|IOBT - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Sutro Biopharma, Inc. (STRO)|INKT - Long-Term Debt to Capital Coefficient|werewolftx.com - Long-Term Debt to Capital|IMMX (Immix Biopharma) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALXO|Long-Term Debt to Equity Ratio CUE|Long-Term Debt to Equity PDSB (PDS Biotechnology)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|Long-Term Debt to Equity Ratio MAIA (MAIA Biotechnology, Inc.)|Liminatus Pharma Inc. - Long-Term Debt to Capital|Lava Tx (LVTX) - Long-Term Debt to Equity|NXTC: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity LPTX|Long-Term Liabilities to Capital Intensity Therapeutics, Inc.|Sensei Biotherapeutics Inc - Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity Theriva Biologics Inc (TOVX)|Long-Term Debt to Equity Ratio Gritstone bio, Inc.|Long-Term Loans to Capital Ratio Kineta Corp (KA)|Long-Term Debt to Capital NexImmune, Inc.|Long-Term Debt to Capital Coefficient Turnstone Biologics Corp TSBX|VCNX (Vaccinex) - Long-Term Debt to Capital|HARP: Long-Term Liabilities to Capital